Announcements Trials
Browse Landscape

Phase

Phase NA 9Phase 2 2Phase 1/2 2Phase 1 1

Status

Unknown 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 6Head & Neck 2Genitourinary 2Gynecologic 1Dermatologic 1

Conditions

Prostatic Neoplasms 1Kidney Neoplasms 1

Interventions

Docetaxel 191Gemcitabine 148Prednisone 142pembrolizumab 125enzalutamide 119Abiraterone Acetate 108Nivolumab 107Cisplatin 103Magnetic Resonance Spectroscopy 100Radiotherapy 95Sunitinib 94Leuprolide 91Carboplatin 82Specimen Handling 71Androgen Antagonists 63bicalutamide 60Radiosurgery 60Paclitaxel 59Goserelin 59Ipilimumab 57Bevacizumab 57apalutamide 53Sorafenib 53acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 51Everolimus 49cabozantinib 48abiraterone 46atezolizumab 45cabazitaxel 43durvalumab 42

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Electroporation × Genitourinary × Clear all
NCT01835977 2020-12-16

Multi-Center Randomized Clinical Trial Irreversible Electroporation for the Ablation of Localized Prostate Cancer

Clinical Research Office of the Endourological Society

Phase 2 Unknown
106 enrolled
Genitourinary

Prostatic Neoplasms

NCT02828709 2016-09-27

Safety and Feasibility of IRE for SRMs

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Phase 2 Unknown
20 enrolled
Genitourinary

Kidney Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡